慢性丙型肝炎干扰素治疗后复发患者的聚乙二醇干扰素联合利巴韦林再治疗.docVIP

慢性丙型肝炎干扰素治疗后复发患者的聚乙二醇干扰素联合利巴韦林再治疗 目录 TOC \o 1-9 \h \z \u 目录 1 正文 1 文1：慢性丙型肝炎干扰素治疗后复发患者的聚乙二醇干扰素联合利巴韦林再治疗 1 1 资料与方法 3 2 结果 4 3 讨论 5 文2：聚乙二醇干扰素α2a联合利巴韦林对慢性丙型肝炎患者疗效的观察 6 1 材料与方法 6 2 结 果 7 3 讨 论 8 参考文摘引言： 10 原创性声明（模板） 11 文章致谢（模板） 11 正文 慢性丙型肝炎干扰素治疗后复发患者的聚乙二醇干扰素联合利巴韦林再治疗 文1：慢性丙型肝炎干扰素治疗后复发患者的聚乙二醇干扰素联合利巴韦林再治疗 Retreatment with peginterferon alfa-2a plus ribavirin in patients with relapsed chronic hepatitis C 【Abstract】 Objective To evaluate the efficacy and investigate the influencing facto of the peginterferon alfa-2a （PEG-IFNα-2a） plus ribavirin retreatment for patients with chronic hepatitis C（CHC） relapsed after a previous IFN A retrospective study was designed to analyze the retreatment with PEG-IFNα-2a of 50 relapsed CHC patients. The influence of HCV RNA load in serum and genotype to the therapy were analyzed. Results Among all the patients the sustained viral respoe （SVR） rate was %. The non-sustained viral respoe （VR） rates was %. The SVR rate of patients with high viral loads（HCV RNA≥1×107copies/ml） was %; The SVR rate of patients with low viral loads（HCV RNA1×104copies/ml） was %. There was a significant differences in the SVR rate of patients between low and high viral loads（OR：，95% CI ～ ， P）. The SVR rate of patients with HCV genotype 2a or 2b was %; The SVR rate of patients with HCV genotype 1b was %. There was not a significant differences in the SVR rate of patients between the different genotypes（OR：，95%CI ～ ，P）.Conclusion The CHC patients with low viral loads were more likely to show SVR compaired with those of high low viral loads. Differences in HCV genotypes may not influence the respoe to the Retreatment with PEG-IFNα-2a plus ribavirin in patients with relapsed chronic hepatitis C. 【Key words】 Hepatitis C virus; chronic hepatitis C; relapse; interferon alfa; polyethylene glycols 丙型肝炎病毒（HCV）感染是导致肝硬化及肝细胞癌等晚期肝病的主要病因之一，抗病毒治疗能改善肝脏炎症、抑制肝纤维化及防止病情进展。但是由于HCV基因的高度变异性和病毒能感染肝脏外其他组织细胞，使病毒很难清除， 并且在病程中反复发作，其干扰素（IFN）治疗后复发率约%～%